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Ron Ram,1 Barry Storer,1,2 Marco Mielcarek,1,2 Brenda M. Sandmaier,1,2
David G. Maloney,1,2 Paul J. Martin,1,2 Mary E. D. Flowers,1,2
Bee K. Chua,2 Marcello Rotta,1 Rainer Storb1,2To determine whether calcineurin inhibitor (CNI) blood concentrations within the first month after
allogeneic hematopoietic cell transplantation (HCT) correlated with the incidence of graft-versus-host
disease (GVHD) and other outcomes, we retrospectively analyzed data from 1181 patients with hematologic
malignancies who had HCT from HLA-matched related (n5 634) or unrelated (n5 547) donors at a single
institution between 2001 and 2009. After myeloablative HCT (n 5 774), higher CNI concentrations were
not associated with lower risks of acute or chronic GVHD (aGVHD, cGVHD). After nonmyeloablative
HCT (n 5 407), higher cyclosporine concentrations were associated with decreased risks of grade 2-4
and 3-4 aGVHD (hazard ratio [HR] per 100 ng/mL change in cyclosporine concentrations, 0.7; 95% confi-
dence interval [CI], 0.6-0.82; and HR, 0.66, 95% CI, 0.49-0.9, respectively), nonrelapse mortality (HR, 0.6,
95% CI, 0.41-0.88), and overall mortality (HR, 0.83, 95% CI, 0.71-0.99). Cyclosporine concentrations
were not associated with risks of cGVHD and recurrent malignancy after nonmyeloablative HCT. Among
patients given tacrolimus after nonmyeloablative HCT, a similar trend of CNI-associated GVHD-protection
was observed. Higher CNI concentrations were not associated with apparent renal toxicity. We conclude
that higher cyclosporine concentrations relatively early after nonmyeloablative HCT confer protection
against aGVHD that translates into reduced risks of nonrelapse and overall mortality.
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Graft-versus-host disease (GVHD) after alloge-
neic hematopoietic cell transplantation (HCT) is
associated with morbidity and mortality [1,2]. The
most commonly used regimens for prevention of
acute GVHD (aGVHD) consist of a combination of
a calcineurin inhibitor (CNI), either cyclosporine
(CSP) or tacrolimus (TAC), and an antimetabolite.
In patients receiving myeloablative conditioning,
CSP and methotrexate (MTX) have been clinically
used for almost 3 decades [3,4]. Subsequently, the1Fred Hutchinson Cancer Research Center, Seattle,
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be at least as effective as CSP and MTX [5,6]. For
patients receiving a nonmyeloablative preparative
regimen, GVHD prophylaxis is frequently based on
a CNI and mycophenolate mofetil (MMF) [7,8].
Although both MTX and MMF are usually given at
fixed doses, CNI dosing is typically adjusted both to
avoid toxicities, especially renal, and to maintain
whole-blood concentrations within a therapeutic
range [9-11].
Among patients given myeloablative HCT, at-
tempts aimed at decreasing administered CSP doses
during the first 10 days irrespective of concentrations
showed that, although incidence and severity of
aGVHD remained unaffected, lower CSP doses were
associated with reduced adverse events [12]. Con-
versely, when CSP concentrations were targeted
instead of adhering to an absolute administered dose,
lower CSP concentrations were associated with
increased grades 2-4 aGVHD [13]. Four other small
cohort studies showed that in patients given myelo-
ablative conditioning, lower CSP concentrations
before engraftment were associated with significantly
Table 1. Patients’ Characteristics
Datum
Conditioning
All Patients
(n 5 1181)
Myeloablative (n 5 774) Nonmyeloablative (n 5 407)
Cyclosporine
(n 5 451)
Tacrolimus
(n 5 323)
Cyclosporine
(n 5 280)
Tacrolimus
(n 5 127)
Sex (female/male, %) 45/55 42/58 40/60 46/54 43/57
Female donor to male recipient (%) 24 26 26 22 25
Patients’ ages, years (median, range) 45 (19-66) 45 (18-67) 56 (18-79) 57 (20-74) 49 (18-79)
Donors’ ages, years (median, range) 40 (10-74) 38 (15-80) 43 (18-83) 46 (20-77) 41 (10-83)
Donor type (related/unrelated, %) 58/42 49/51 52/48 53/47 54/46
PBSC/marrow, % 85/15 86/14 99/1 100/0 91/9
Disease risk (low/high, %) 66/34 72/18 38/62 45/55 59/41
Year of transplantation (n patients)
2001 117 1 51 –– 169
2002 112 1 49 –– 162
2003 114 3 52 1 170
2004 84 21 38 9 152
2005 18 100 21 30 169
2006 3 79 33 18 133
2007 1 47 24 27 99
2008 0 50 5 29 84
1-6/2009 2 21 7 13 43
High-dose regimen (n patients)
TBI-based 152 114 –– –– 266
Non–TBI-based 299 117 –– –– 416
Low-dose regimen (n patients)
Flu-2 (3) Gy TBI –– –– 232 100 332
2 Gy TBI –– –– 48 27 75
Flu indicates fludarabine; PBSC, G-mobilized peripheral blood stem cells.
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[17,18] aGVHD. A large prospective trial, however,
showed only a trend toward an association between
low CSP concentrations and increased risk of
GVHD, whereas no correlation was found between
TAC concentrations and risk of GVHD [10]. Data
for patients receiving nonmyeloablative or reduced-
intensity conditioning regimens are even scarcer,
with only 1 publication reporting data on a mixed
group of patients given either myeloablative or
reduced-intensity conditioning [17].
In the present study, we retrospectively analyzed
data from 2 cohorts of patients who received HCT
from HLA-matched related or unrelated donors with
either myeloablative or nonmyeloablative condition-
ing and who were treated with either CSP or TAC-
based immunosuppression. Each cohort was analyzed
for possible associations between CNI concentrations
and incidence and severity of aGVHD among other
transplantation outcomes.PATIENTS AND METHODS
Patients
Patients who received allogeneic HCT between
January 2001 and June 2009 at the Fred Hutchinson
Cancer Research Center were identified from a
computerized database. Patients had signed forms ap-
proved by the institutional review board documentinginformed consent to participate in clinical trials and
to allow the use of medical information for research.
To be included in the study, patients had to be at least
18 years old and receive their first allogeneic trans-
plant for hematological malignancy from an HLA-
identical sibling or 10 of 10 HLA antigen-matched
unrelated donors. HLA typing was performed with
intermediate- or high-resolution molecular matching
for HLA-A, -B, -C, -DRB1, and -DQB1. Only pa-
tients who received a CNI and MTX after
myeloablative conditioning or a CNI and MMF after
nonmyeloablative conditioning were included. Pa-
tients receiving second allogeneic HCT were ex-
cluded. Patient characteristics are listed in Table 1.
Preparative Regimen and Immunosuppression
Treatment
Myeloablative conditioning regimens were either
total body irradiation (TBI)-based (primarily intrave-
nous cyclophosphamide; 60 mg/kg per day for 2 con-
secutive days followed by fractionated TBI, 12 Gy) or
non–TBI-based (primarily oral busulfan; 4 mg/kg per
day for 4 consecutive days and intravenous cyclophos-
phamide (60 mg/kg per day for 2 consecutive days)).
Nonmyeloablative conditioning regimens included
low-dose TBI (2-3 Gy) with or without fludarabine
(30 mg/m2 body surface area/day for 3 consecutive
days) [19].
For patients receiving myeloablative conditioning,
the intravenous CNI was started on day 21
416 Biol Blood Marrow Transplant 18:414-422, 2012R. Ram et al.before HCT. Intravenous CSP was administered at
3 mg/kg/day given in 2 divided doses every 12 hours
at 1.5 mg/kg each dose and infused over a period of 1
hour. TAC was given at 0.03 mg/kg/day (1.25 mg/kg/
h) by continuous intravenous infusion. Intravenous
medications were usually discontinued once patients
started to eat, and drugs were switched to oral formu-
lations. For patients receiving nonmyeloablative con-
ditioning, the CNI was started on day 23 before
HCT. CSP was given either orally at 5-6.25 mg/kg
twice daily or intravenously at 2.5 mg/kg twice daily.
TAC was given orally at a dose of 0.06 mg/kg twice
daily. All initial dose calculations were based on
adjusted body weights.
CNI levels were based on trough whole-blood
concentrations. As a general rule, if patients received
CNIs intravenously, trough concentrations were
obtained daily before the next dose was administered.
If patients were treated with an oral formulation,
trough concentrations were obtained in the morning,
twice weekly, before the next dose.
Measurements of whole-blood TAC levels were
performed using the IMx assay [20]. During the initial
study period, CSP concentrations were measured by
monoclonal or polyclonal antibody assay. Starting in
July 2007, CSP concentrations were measured by
high-pressure liquid chromatography [21]. For the
purpose of a uniform statistical analysis, a correction
factor of 0.80 has been applied to all CSP concentra-
tions measured by monoclonal or polyclonal antibody
assay to adjust the antibody assay values to the high-
pressure liquid chromatography values. In general,
for the first 28 days, CNI concentrations in nonmye-
loablative patients were targeted higher than in
myeloablative patients, and TAC and CSP doses
were adjusted to maintain whole concentrations of
5-20 ng/mL and 200-500 ng/mL, respectively.
In addition to CNIs, patients receiving myeloabla-
tive conditioning were treated with intravenous MTX
(15 mg/m2 on day 1; 10 mg/m2 on days 13, 16, and
111). For patients receiving nonmyeloablative condi-
tioning, administration of MMF was started 4-6 hours
afterHCTat a dose of 15mg/kg given 2 or 3 times daily
for recipients of related or unrelated grafts, respectively.
If necessitated by the onset of GVHD, toxicity, or
management of persistent or recurrent malignancy,
doses and tapering schedules of immunosuppressive
agents were modified at the discretion of the attending
physicians. However, withdrawal of immunosuppres-
sive medications was rarely initiated before day 28.GVHD Evaluation and Treatment
Acute GVHD was diagnosed and graded accord-
ing to the current grading system [22]. For patients
who developed aGVHD during the taper of immuno-
suppressive medications, the CNI taper was held anda therapeutic CNI dose was reinstituted. For most
patients, systemic glucocorticoids were used for initial
treatment of GVHD. After 7-10 days, if GVHD
symptoms had resolved, a glucocorticoid taper was
initiated [23].
For the purpose of evaluatingCNI-associated renal
toxicity, the day 14 and 28 glomerular filtration rate
(GFR) was calculated using the Cockcroft and Gault
formula, CCr 5 [(140-age)  weight]/(72 SCr) 
0.85, if female [24].
Statistical Analysis
Cumulative incidence curves for aGVHD were
estimated using methods previously described [25].
Cox regression analysis was used to model the impact
of CNI levels on time-to-event endpoints. Death and
relapse were treated as competing risks for analysis of
aGVHD and chronic GVHD (cGVHD). Relapse
was treated as a competing risk for the analysis of
nonrelapse mortality (NRM). The effects of CNI
levels on hazard ratios (HRs) were expressed as per
100 ng/mL increase of CSP and 5 ng/mL increase of
TAC (both were approximately the interquartile
ranges for both myeloablative and nonmyeloablative
patients). Mean CNI levels were calculated for the first
and second week and were treated as fixed covariates.
Cumulative mean CNI up to day 130 was treated as
a time-dependent covariate, that is, at each time the co-
variate represented the mean of all prior levels up to
the onset of GVHD or day 130, whichever occurred
first. We decided to use the week 2 time point because
it was after initial dose adjustments had beenmade, but
before most GVHD occurred. Overall, results were
similar for the 3 different time points. Simple linear
regression was used to correlate mean CNI levels
with maximum bilirubin and alanine transaminase
(ALT) levels during the first month and the maximal
change in creatinine and GFR through day 14 and
day 28. All P values are 2-sided and are not adjusted
for multiple comparisons.RESULTS
Between January 1, 2001, and June 30, 2009,
1181 patients given allogeneic HCT fulfilled study in-
clusion criteria (Table 1). Preparative regimens were
myeloablative or nonmyeloablative for 774 (66%)
and 407 (34%) patients, respectively. CSP was given
to 58% of patients in the myeloablative group and to
69% of those in the nonmyeloablative group. Most
patients (86% and 99.5% in the myeloablative and in
the nonmyeloablative groups, respectively) received
granulocyte colony stimulating factor–mobilized
peripheral blood stem cell grafts. The proportion of
patients given TAC-based GVHD prophylaxis
increased during the study period from 0.6% in 2001
Table 2. Effects of Increasing Week 2 Mean Calcineurin Inhibitors Blood Concentrations Levels as Fixed Covariates on aGVHD,
cGVHD, Relapse Rate, NRM, and OM
Datum
Myeloablative Conditioning (n 5 774) Nonmyeloablative Conditioning (n 5 407)
Cyclosporine (n 5 451) Tacrolimus (n 5 323) Cyclosporine (n 5 280) Tacrolimus (n 5 127)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Acute GVHD 2-4 0.99 (0.87-1.13) .88 1.02 (0.82-1.26) .88 0.70 (0.60-0.82) <.0001 0.77 (0.53-1.13) .18
Acute GVHD 3-4 0.98 (0.71-1.34) .88 1.79 (1.12-2.86) .02 0.66 (0.49-0.90) .008 0.31 (0.11-0.86) .02
Chronic GVHD 1.03 (0.88-1.19) .74 0.93 (0.70-1.24) .61 1.00 (0.83-1.21) .99 1.25 (0.86-1.81) .25
Relapse 0.82 (0.58-1.16) .26 0.91 (0.55-1.51) .71 0.96 (0.72-1.28) .78 1.25 (0.80-1.96) .33
NRM 0.99 (0.76-1.30) .94 1.75 (1.17-2.61) .007 0.60 (0.41-0.88) .008 0.55 (0.19-1.53) .25
OM 0.98 (0.84-1.15) .80 1.18 (0.90-1.54) .22 0.83 (0.71-0.99) .03 0.80 (0.56-1.14) .21
Hazard ratios are given per 100 ng/mL (CSP) or 5 ng/mL (TAC).
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0.6-9) years. CNI concentrations were monitored at
least twice weekly, and the mean numbers of concen-
trations assessed per patient during the first month
were 10 and 11 for CSP- andTAC-treated patients, re-
spectively. Correlation between mean CNI and me-
dian CNI in our cohort was approximately 0.98 for
each group. Among myeloablative patients, week 2
mean CSP and TAC concentrations were 261 ng/mL
and 11.7 ng/mL, respectively. Among nonmyeloabla-
tive patients, week 2 mean CSP and TAC concentra-
tions were 409 ng/mL and 13.7 ng/mL, respectively.
There was some trend of change in the mean CNI
levels over years of treatment (2001-2009), but the
effect size was only 1% to 2% per year relative to the
overall mean levels. For patients given myeloablative
conditioning with either CSP or TAC, there were
5.1 ng/mL (P 5 .10) and 20.31 ng/mL (P 5 .01)
changes in the CNI blood concentration, respectively.
For patients given nonmyeloablative conditioning
with either CSP or TAC, there were 24.4 ng/mL
(P 5 .10) and 2.28 ng/mL (P 5 .20) changes in the
CNI blood concentration, respectively.Acute GVHD
Incidence of grade 2-4 aGVHD decreased over
the years of treatment (2001-2009), but the effect
size was small. For patients given myeloablative and
nonmyeloablative conditioning, hazard ratios for
grade 2-4 aGVHD were 0.94 (P 5 .002) and 0.94
(P 5 .02) for each year. For patients given myeloabla-
tive conditioning, median time to aGVHD onset was
24 (3-119) days, whereas for patients given nonmye-
loablative conditioning the median was 34 (5-151)
days (P\ .0001).
Myeloablative Conditioning
Of the 774 patients given myeloablative condi-
tioning, 451 (58%) were treated with CSP and 323
(42%) with TAC (Table 2). Grade 2-4 aGVHD
was documented in 310 (69%) and 228 (71%) pa-
tients, respectively. Grade 3-4 aGVHD was docu-mented in 56 (12%) and 33 (10%) patients,
respectively. We found no correlations between
week 2 mean CNI concentrations and risk of grade
2-4 aGVHD either in patients given CSP or TAC
(HR 5 0.99, 95% confidence interval [CI]: 0.87-
1.13, P 5 .88; and HR 5 1.02, 95% CI: 0.82-1.26,
P 5 .88, respectively). We also found no correlation
between week 2 mean CSP concentrations and the
risk of grade 3-4 aGVHD (HR 5 0.98, 95% CI:
0.71-1.34, P 5 .88). Unexpectedly, higher week 2
mean TAC concentrations were correlated with
a higher risk of grade 3-4 aGVHD (HR 5 1.79,
95% CI: 1.12-2.86, P 5 .02). When the risk of grade
3-4 aGVHD was analyzed according to week 1 mean
TAC concentrations and cumulative mean to GVHD
onset, no correlation was demonstrated (HR 5 0.98,
95% CI: 0.88-1.08, P 5 .63; and HR 5 0.99, 95%
CI: 0.93-1.05, P 5 .65, respectively).
Nonmyeloablative Conditioning
Of the 407 patients given nonmyeloablative condi-
tioning, 280 (69%) were treated with CSP and
127 (31%) with TAC (Table 2). Grade 2-4 aGVHD
was documented in 184 (66%) and 49 (39%) patients,
respectively. Grade 3-4 aGVHD was documented in
47 (17%) and 8 (6%) patients, respectively. Among
patients who were treated with CSP, a higher week 2
mean concentration was associated with a decreased
risk of both grades 2-4 and 3-4 aGVHD (HR 5 0.7,
95% CI: 0.6-0.82, P\ .0001; and HR 5 0.66, 95%
CI: 0.49-0.9, P 5 .008, respectively). Thus, for each
100 ng/mL increase in the CSP concentration, we
observed a 30% and 34% decrease in the risks of
grades 2-4 and 3-4 aGVHD, respectively. Analysis of
GVHD incidence in quartiles of patients grouped
according to week 2 mean CSP concentrations showed
inferior control of grades 2-4 and 3-4 aGVHD in the
lower quartiles (Figure 1A-B).
When recipients of grafts from related and unre-
lated donors were analyzed separately, we did not
observe a statistically significant difference in the cor-
relation betweenCSP concentration and acute GVHD
(grade 2-4, P 5 .19; grade 3-4, P 5 .21).
Figure 1. Association of mean week 2 CSP (A, B) and TAC (C, D) concentrations with the cumulative incidence of grade 2-4 (A, C) and grade 3-4 (B, D)
aGVHD after HCTwith nonmyeloablative conditioning. CNI concentrations were divided according to quartiles.
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mean TAC concentrations and the risk of grade 2-4
aGVHD (HR 5 0.77, 95% CI: 0.53-1.13, P 5 .18)
(Table 2). Nonetheless, higher mean week 2TAC con-
centrations were associated with a decreased risk of
grade 3-4 aGVHD (HR 5 0.31, 95% CI: 0.11-0.86,
P 5 .02). Analysis of GVHD incidence in quartiles
of patients grouped according to week 2 mean TAC
concentrations suggested inferior control of grade
3-4 aGVHD in the lowest quartile (\10.5 ng/mL)
(Figure 1C-D).
Other Transplantation Outcomes (Table 2)
Chronic GVHD
Among recipients of myeloablative HCT given
either CSP or TAC, we found no correlations between
week 2 mean CNI concentrations and risk of
cGVHD (HR 5 1.03, 95% CI: 0.88-1.19, P 5 .74
and HR 5 0.93, 95% CI: 0.7-1.24, P 5 .61, respec-
tively) (Table 2). This was also true for patients receiv-
ing nonmyeloablative conditioning (HR 5 1.00, 95%
CI: 0.83-1.21, P 5 .99 and HR 5 1.25, 95% CI:
0.86-1.81, P 5 .25, respectively).
Relapse
Among recipients of myeloablative HCT given
either CSP or TAC, we found no correlation between
week 2 mean CNI concentrations and the risk of
relapse (HR 5 0.82, 95% CI: 0.58-1.16, P 5 .26 and
HR 5 0.91, 95% CI: 0.55-1.51, P 5 .71, respectively)
(Table 2). Similarly, for recipients of nonmyeloablativeHCT, we found no correlation between week 2 mean
CNI concentrations and risk of relapse (HR 5 0.96,
95% CI: 0.72-1.28, P 5 .78 and HR 5 1.25, 95% CI:
0.80-1.96, P 5 .33, respectively).
There was no correlation between mean week 2
CNI levels with day 28 CD3 chimerism (20.7% per
100 ng/mL, P 5 .67 in patients given CSP and
10.9% per 5 ng/mL, P 5 .71 in patients given
TAC). This fact might suggest an explanation for the
lack of association between the CNI blood concentra-
tions and the overall risk of relapse.
NRM
Among recipients of myeloablative HCT given
CSP, we found no correlation between week 2 mean
CSP concentrations and risk of NRM (HR 5 0.99,
95% CI: 0.76-1.35, P 5 .03) (Table 2). Among
recipients of myeloablative HCT given TAC, higher
mean week 2 concentrations were correlated with a
higher risk of NRM (HR 5 1.79, 95% CI: 1.17-2.
61, P 5 .007). When NRM was analyzed according
to week 1 mean TAC concentrations and the cumula-
tive mean to GVHD onset, however, no correlation
was demonstrated (HR 5 0.94, 95% CI: 0.86-1.02,
P 5 .12 and HR 5 0.97, 95% CI: 0.84-1.11, P 5
.62, respectively). For recipients of nonmyeloablative
HCT given CSP, higher week 2 mean concentrations
were correlated with a lower risk of NRM (HR5 0.60,
95% CI: 0.41-0.88, P 5 .008). Conversely, for recipi-
ents of nonmyeloablative HCT given TAC, no such
correlation was observed (HR 5 0.55, 95% CI: 0.19-
1.53, P 5 .25).
Figure 2. Correlation of mean week 2 CNI concentrations in patients treated with CSP (A, C) or TAC (B, D) with the maximal change in GFR during
the first 4 weeks after HCTwith myeloablative conditioning (A, B) or nonmyeloablative conditioning (C, D).
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Among recipients of myeloablative HCT given
either CSP or TAC, we found no correlation between
week 2mean concentrations and risk of overall mortal-
ity (OM) (HR5 0.98, 95% CI: 0.84-1.15, P5 .80 and
HR 5 1.18, 95% CI: 0.9-1.54, P 5 .22, respectively)
(Table 2). For recipients of nonmyeloablative HCT
given CSP, we found a correlation between higher
week 2 mean CSP concentrations and lower OM
(HR 5 0.83, 95% CI: 0.71-0.88, P 5 .008). Con-
versely, for recipients of nonmyeloablative HCT given
TAC, no such correlation was observed (HR 5 0.80,
95% CI: 0.56-1.14, P 5 .21).
Renal Toxicity
In both recipients of myeloablative and nonmye-
loablative HCT, higher week 2 mean CSP concentra-
tions were not significantly correlated with the
maximal increase in creatinine concentration or with
the maximal decrease in GFR during the first 4 weeks
after HCT (Figure 2).
For patients given myeloablative conditioning and
TAC, higher week 2 mean concentrations were signif-
icantly correlated with both the maximal increase in
creatinine concentration and the maximal decrease in
GFR during the first 4 weeks after HCT, although
the effect was small (estimated effect 0.16 mg/dL,standard error 0.06, P5 .004 and23.1 mL/min, stan-
dard error 1.5, P5 .03). For patients conditioned with
nonmyeloablative regimens, higher week 2 mean TAC
concentrations were significantly correlated only
with the maximal decrease in GFR during the first
4 weeks, although the effect was small (estimated effect
22/9 mg/dL, standard error 1.1, P 5 .01).
Results were similar for the subgroup of patients
who received HCT with nonmyeloablative condition-
ing for treatment of multiple myeloma, who were
presumed to be at a higher risk of renal toxicity.Liver Toxicity
In both recipients of myeloablative and nonmye-
loablative HCT, higher week 2 mean CSP concentra-
tions were not significantly correlated with increases
in liver bilirubin or ALT during the first 4 weeks
after HCT.
For patients given myeloablative conditioning with
CSP or TAC, concentration increases of 100 ng/mL
and 5 ng/mL, respectively, were associated with
changes in bilirubin of 0.6 units (P5 .52) and 1.4 units
(P5 .16), respectively, and changes in ALT of 1.4 units
(P 5 .18) and 20.2 units (P 5 .86).
For patients given nonmyeloablative conditioning
with CSP or TAC, increases in 100 ng/mL and
5 ng/mL, respectively, were associated with changes
420 Biol Blood Marrow Transplant 18:414-422, 2012R. Ram et al.in bilirubin of 22.5 units (P 5 .01) and 20.30 units
(P 5 .77), respectively, and changes in ALT of
21.8 units (P 5 .08) and 20.70 units (P 5 .50).DISCUSSION
This retrospective study that included data from
1181 patients given hematopoietic cell grafts from
HLA-matched related and unrelated donors showed
that among patients given myeloablative conditioning,
higher week 2 mean whole blood concentrations of
CNIs did not lead to decreased incidence or severity
of aGVHD. Among patients given nonmyeloablative
HCT, in contrast, relatively high CSP levels early after
HCT predicted both a lower incidence and lessened
severity of aGVHD. For patients given TAC, higher
levels were only correlated with protection against
grade 3-4 aGVHD. Consistent with the findings by
others, we did not find associations between high
CNI concentrations and cGVHD [17].
Other investigators have analyzed relationships
betweenCSPconcentrations and incidence and severity
of aGVHD after myeloablative HCT [10,13-18]. All
studies except 1 [10] were small and retrospective, and
GVHDprophylaxis, sometimeswith additionof antith-
ymocyte globulin, was not always uniform [13,16-18].
Most of these studies showed that low CSP
concentrations early after myeloablative HCT were
associated with higher risk of aGVHD [13-16,18].
Conversely, a large prospective randomized trial
comparing CSP-MTX with TAC-MTX showed only
a trend between low CSP concentrations and high risk
of GVHD, but no such correlation in patients given
TAC [10]. Among current recipients of myeloablative
HCT, we found no correlation between CSP concen-
trations and risk of aGVHD. Unexpectedly, higher
week 2 mean TAC concentrations were associated
with higher risks of both grade 3-4 aGVHD and
NRM,but this counterintuitive correlationdisappeared
when TAC concentrations were analyzed at other time
points.We speculate that this association was probably
related to undefined confounders andnot to an inherent
effect of early TAC concentrations.
Data on possible correlations between CNI con-
centrations and outcomes after nonmyeloablative
HCT are scarce. To minimize the risk of graft rejec-
tion after nonmyeloablative HCT, CNI concentra-
tions have typically been targeted to higher levels
than after myeloablative HCT. Here we showed that
for patients given CSP, higher week 2mean concentra-
tions were correlated with lower incidence and severity
of aGVHD. In patients given TAC, higher week 2
mean levels were correlated only with the risk of grade
3-4 aGVHD, whereas no correlation was observed
with grade 2-4 aGVHD, possibly reflecting the smaller
sample size (only 31% of nonmyeloablative patientsreceived TAC) and the small number of aGVHD
cases.
Reasons for the differential impact of CNI blood
level variations on outcomes after HCT with myeloa-
blative and nonmyeloablative conditioning are unclear.
One could speculate that (1) the protective effect
associated with higher CNI concentrations could not
be fully assessed in myeloablative patients where CNI
levels are maintained in relatively low therapeutic
ranges, and (2) the benefit associated with higher
CNI concentrations after nonmyeloablative HCT
might be related to the use of MMF instead of MTX.
It is also recognized that the clinical and immuno-
biological characteristics of aGVHD differ according
to conditioning intensity [26]. Comparedwithmyeloa-
blative HCT, nonmyeloablative HCT is associated
with only minimal tissue injury, initial persistence of
host antigen-presenting cells, and a transient state of
mixed chimerism [27,28]. Given that the tissue milieu
after nonmyeloablative conditioning appears to be
overall less ‘‘inflammatory’’ than after myeloablative
conditioning, increased CNI levels may have GVHD
protective effects in the former setting while not
providing an incremental therapeutic benefit in the
myeloablative setting.
After nonmyeloablative HCT, protection against
aGVHD associated with higher CSP concentrations
early after transplantation translated into decreased
risks of NRM and OM. Importantly, the benefit of
GVHD protection in this setting was not outweighed
by an increased risk of recurrent malignancy. Similar
trends, although not statistically significant, were
observed in patients given TAC. After myeloablative
HCT, no correlations between CNI concentrations
and long-term outcomes (relapse, NRM, and OM)
were observed.
Based on our observations, we recommend that
patients given nonmyeloablative conditioning and
CSP- or TAC-based postgrafting immunosuppression
in combination with MMF should have their CNI
doses targeted to relatively high blood concentrations
early after transplantation. At a minimum, concentra-
tions should be targeted above the lowest quartile
range in our study, which is equivalent to 345 ng/mL
for CSP and 10.5 ng/mL for TAC. Our results further
suggest that CSP concentrations above 345 ng/mL
provide incremental protection against grades 2-4
and grades 3-4 aGVHD whereas TAC concentrations
above 10.5 ng/mL did not appear to provide any incre-
mental GVHD protection. The absence of clinically
significant renal and liver impairment associated with
higher CNI concentrations early after HCT further
supports our recommendation, even in patients with
multiple myeloma. Nonrenal or liver CNI-associated
toxicities, however, were not analyzed in this retro-
spective study. Nevertheless, these recommendations
apply only to patients given truly nonmyeloablative
Biol Blood Marrow Transplant 18:414-422, 2012 421Calcineurin Inhibitor Concentrations and Acute GVHDconditioning and cannot be extrapolated to patients
given other reduced-intensity regimens.
Our finding that high CSP levels translate into
improved survival are remarkable in light of the fact
that modifications of prophylactic regimens against
aGVHD, with only few exceptions, rarely translated
into reduced risks in mortality [3,4,29,30]. Our
group reported recently, for example, that even
though donor statin treatment was associated with
a profoundly decreased risk of grades 3-4 aGVHD,
this benefit did not translate into improved overall
survival [31]. The statistical power in the current study
was not sufficient to determine whether the same ob-
servation applies for TAC, but it is noteworthy that
point estimates for the association of higher CNI con-
centrations with decreased risks of mortality are simi-
lar for the 2 drugs.
In conclusion, within the limits of a retrospective
study, we provide evidence that after HCT with non-
myeloablative conditioning, higher CNI concentra-
tions in conjunction with MMF are associated with
decreased risks of aGVHD, NRM, and OM. The
benefits and risks of targeting high CNI concentra-
tions early after nonmyeloablative HCT should be
confirmed in prospective clinical trials.ACKNOWLEDGMENTS
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